Supplement: Who Gets Immunotherapy for Cancer?
Managing Patient Expectations Requires Better Biomarkers and Companion Diagnostics Read the full article at GEN News Improving Cancer Immunotherapy...
TruCulture System Proves Superior Reproducibility Over PBMCs
Standardized whole blood stimulation system proves superior reproducibility over PBMCs A new paper on improved methods for monitoring differential im...
Inflammatory Cytokines as Potential Biomarker for Pain Intensity
Biomarkers for pain assessment are needed for more accurate pain therapy treatment in patients unable to reliably self-report their circumstances such...
Phase I Clinical Results from FR104, a mAb Specific to CD28
Researchers led by Bernard Vanove of OSE Immunotherapeutics report in the December 7, 2016 issue of the Journal of Immunology on the first-in-human st...
Myriad RBM Announces an Agreement with Sanofi to Measure Predictive Cardiovascular Biomarkers in Patients with Diabetes
Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com ...
Myriad RBM’s TruCulture® and Gene Expression Profiling Characterizes Immune Response in Landmark Study Led by Institut Pasteur
Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com ...
Myriad RBM DiscoveryMAP® Technology Identifies Novel Biomarkers that May Predict Increased Risk of Cardiovascular Events in Patients with Diabetes
Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com ...